SCHEMBL5773746

SCHEMBL5773746

CC(=O)Oc1cc2cc(C(=O)CN3CCOCC3)oc2c(C)c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.43
MAPT P10636 6/20 0.43
MAPK1 P28482 1/20 0.43
APP P05067 1/20 0.41
LMNA P02545 3/20 0.40
HSP90AA1 P07900 2/20 0.40
HSP90AB1 P08238 2/20 0.40
GAA P10253 2/20 0.40
HTT P42858 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
TP53 P04637 1/20 0.38
THRB P10828 1/20 0.38
TSHR P16473 2/20 0.38
POLB P06746 2/20 0.38
ALOX15 P16050 1/20 0.38
PKM P14618 1/20 0.37
HPGD P15428 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5769835 0.82 ALDH1A1 (0.47) ALDH1A1MAPTMAPK1APPHTT
SCHEMBL5772244 0.78 CA12 (0.38) ALDH1A1MAPTMAPK1LMNAHSP90AA1
SCHEMBL5892600 0.76 LMNA (0.47) ALDH1A1MAPTLMNAHSP90AA1HSP90AB1
SCHEMBL5771969 0.75 LMNA (0.39) MAPTLMNAHSP90AA1HSP90AB1HTT
SCHEMBL5769687 0.64 CA12 (0.32) POLB
SCHEMBL28054865 0.64 KMT2A (0.44) ALDH1A1MAPTLMNAHTTMEN1
SCHEMBL5772217 0.64 RAB9A (0.49) ALDH1A1HSP90AA1HSP90AB1HTTMEN1
SCHEMBL16741170 0.63 KMT2A (0.59) ALDH1A1MAPTMAPK1HTTMEN1
SCHEMBL6763629 0.61 POLB (0.63) ALDH1A1GAAMEN1KMT2APOLB
SCHEMBL16742735 0.60 CXCR4 (0.50) MAPTLMNAHTTTSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7078541-B2 Benzofuran derivatives GALILEO PHARMACEUTICALS, INC. (US) 2006-07-18 US disclosed
EP-1472241-A4 CYTOPROTECTIVE BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS INC (US) 2005-06-29 EP disclosed
WO-2005027900-A1 BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed
EP-1472241-A1 CYTOPROTECTIVE BENZOFURAN DERIVATIVES Galileo Pharmaceuticals, Inc. (US) 2004-11-03 EP disclosed
US-20040063975-A1 Benzofuran derivatives EDISON PHARMACEUTICALS, INC. 2004-04-01 US disclosed
US-6653346-B1 Amtiischemic and antiinflammatory agents GALILEO PHARMACEUTICALS, INC. 2003-11-25 US disclosed
WO-2003066618-A1 CYTOPROTECTIVE BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS, INC. (US) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063975-A1 Benzofuran derivatives NDUFAB1, AIFM1, NDUFAF1 ALDH1A1 404/4885MAPT 278/4885MAPK1 3796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.